We are delighted to announce the opening of our new Paris office. This to serve our increasing French customer base and in continuation of our strategic global expansion. This is NDA’s fifth European location, having offices in Stockholm, London, Munich and Zürich.
We are strengthening our resources in France to provide the highest level of support to our clients. The Paris office will complement the existing capabilities in other European offices to support more frequent client interactions and strategic regulatory support on site.
Johan Strömquist, CEO of NDA Group commented:
“NDA has had close relationships with many of the drug developing companies in France and French speaking Europe for many years. I am therefore delighted to finally be able to announce the opening of our new offices in one of the most prominent capitals of the EU.”
“NDA having a presence in Paris is important to our French clients and other drug development companies in the area. It gives faster access to our great pool of expertise and makes it even easier to communicate across the borders. Ultimately I believe this will help French companies develop their products even better than today and reach the patients they’re targeting even faster.”
NDA’s Paris expansion comes close at the heels of the company’s significant expansion in the US. The office will serve as a platform to help French companies reach the market in Europe, as well as in the States.
Dr. Laurie Smaldone Alsup, MD, CSO and COO of NDA Group commented:
“We are so excited about our new office. The Paris office provides a critical location in Europe to service a range of biotech and pharmaceutical companies within France and environs that are easily accessed from this international hub. We will begin with direct business development and outreach to make our global services and our amazing people known to a broader client base.”
NDA has, since many years, had experts based in France and other parts of French speaking Europe.
Dr. Mira Pavlovic-Ganascia, MD, HTA expert at NDA Group and Deputy Director for Health Technology Assessment at the Hauté Autorité de Santé (HAS) comments:
“NDA, bienvenue à Paris. Big and small companies and current and future partners in France and from French speaking neighbor countries are sure to benefit from support in our domains of excellence – regulatory and HTA – to rapidly bring medicines to the world.”
Laurie Smaldone Alsup
Chief Medical And Scientific Officer